Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ...
Study on axi-cel infusion in 62 aggressive B-cell non-Hodgkin lymphoma patients showed a 71.0% complete metabolic response (CMR) at 3 months. Secondary outcomes included a 75.8% objective response rate (ORR) at 3 months and 59.7% CMR at 6 months. Adverse effects were common, with 95.2% experiencing grade 3 or higher effects, including neutropenia and infections like COVID-19. Efficacy and safety were consistent across age and comorbidity subgroups.
Reference News
Study on axi-cel infusion in 62 aggressive B-cell non-Hodgkin lymphoma patients showed a 71.0% complete metabolic response (CMR) at 3 months. Secondary outcomes included a 75.8% objective response rate (ORR) at 3 months and 59.7% CMR at 6 months. Adverse effects were common, with 95.2% experiencing grade 3 or higher effects, including neutropenia and infections like COVID-19. Efficacy and safety were consistent across age and comorbidity subgroups.